# A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

> **NCT04880031** · PHASE2 · COMPLETED · sponsor: **Boston Pharmaceuticals** · enrollment: 231 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** Efimosfermin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04880031
- **Lead sponsor:** Boston Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-30
- **Primary completion:** 2025-10-27
- **Final completion:** 2025-10-27
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2025-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04880031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04880031, "A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04880031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*